DCS IN ANTIVIRAL IMMUNITY
Efficient antiviral immunity involves both innate and adaptive immune responses. Innate immunity, mediated by proteins (cytokines, acute phase proteins, and complement) and cells (natural killer [NK] cells, phagocytes, and cells that release inflammatory mediators) provides a rapid response that inhibits the progression of the infection. Adaptive immunity, in contrast, leads to viral clearance and generates long-term immunological memory through the generation of specific T and B cells. DCs orchestrate the development of adaptive immunity. Located in all tissues in an immature state, they serve as sentinels in charge of identifying pathogenic invaders. Upon recognition of pathogens, they change their expression pattern of proinflammatory genes, including those coding for cytokines, chemokines, and costimulatory molecules, in a process known as DC maturation. These functional changes are necessary for initiating adaptive immunity (8, 86) . Two major DC populations participate in the development of antiviral immune responses: cDCs and pDCs. cDCs are found in peripheral tissues and secondary lymphoid organs (108) , mature in the presence of virus, and efficiently process and present antigens in the lymph nodes to initiate the adaptive immune response (16) . pDCs, found primarily in blood and secondary lymphoid organs (108) , produce high levels of type I interferons (IFNs) upon binding of virus components to TLRs (9, 42) . It is speculated that pDCs have an important role in antiviral immunity; however, they have poor antigen presentation ability and their physiological role remains controversial (5, 44, 58) .
TLRS IN THE DEVELOPMENT OF ANTIVIRAL IMMUNITY
TLRs are membrane-bound receptors that can be activated by the binding of molecular structures conserved among families of microbes. More than 10 different TLRs have been identified to date. They are highly conserved among mammals and are expressed in a variety of cell types. Numerous reviews describe these molecules and their role in innate immunity (24, 34, 82, 100, 101) .
TLRs specifically activated by various viral elements have been identified. TLR3 binds the viral replication intermediary double-stranded RNA (dsRNA) (2) . TLR7 binds singlestranded RNA (ssRNA), the genomic material of many viruses, such as influenza virus and Sendai virus (SeV) (20, 33) . TLR9 binds CpG motifs found in the genomic DNA of viruses such as herpes simplex virus (HSV) (51, 64) and murine cytomegalovirus (MCMV) (99) . Additionally, some TLRs respond to viral proteins, such as the respiratory syncytial virus fusion protein (TLR4) (32, 53) and the measles virus hemagglutinin protein (TLR2) (12) . TLR binding and stimulation by pathogen-associated molecules is followed by a cascade of intracellular events that culminate in the expression of multiple genes. TLR signaling is mediated primarily by the adaptor protein myeloid differentiation factor 88 (MyD88) that triggers the activation of transcription factors, such as NF-B, that are essential for the expression of proinflammatory genes (77, 100) . This pathway also leads to po-tent production of type I IFNs through the activation of the transcription factor IFN regulatory factor 7 (IRF-7) upon stimulation of TLR7 or TLR9 (48, 77, 91) . In contrast, in response to TLR3 or TLR4 stimulation, it is the Toll/interleukin-1 receptor domain-containing adaptor protein inducing IFN-␤ (TRIF) that mediates the production of type I IFNs primarily through the activation of IRF-3 (36, 113, 114) .
Compelling evidence demonstrates that TLR signaling leads to DC maturation (reviewed in references 46, 72, and 87) . Based on the crucial role of DCs in the generation of adaptive immune responses, it has been extensively argued that TLR signaling is necessary for adaptive antiviral immunity (13, 37, 46, 87) . Nevertheless, most of the existing data showing a role for TLR signaling in the clearance of viral infections may be explained by the innate immune effects of type I IFNs. TLR3 contributes partially to protection against MCMV (99) through innate immune activation. TLR9 leads to type I IFN production in mice infected with HSV (51, 64) and participates in the clearance of MCMV (50, 99) . TLR7 signaling results in type I IFN production in response to infection with vesicular stomatitis virus (VSV) (65) . Also, there is a generalized effect of TLR3, -4, -5, -7, and -9 signaling in controlling replication of the hepatitis B virus through the induction of type I IFNs (41) . A number of reports using mice deficient in the adaptor molecule MyD88 claim an important role for TLRs in the development of adaptive antiviral immunity (69, 115, 120) . Since signaling of the Th1-driving cytokines interleukin 18 (IL-18) and IL-1 in these animals is impaired (1), these data do not constitute conclusive evidence for the involvement of TLR signaling in the generation of antiviral adaptive immunity.
TYPE I IFN IN VIRUS-INDUCED DC MATURATION
Type I IFNs (IFN-␣, -␤, -, and -) can be synthesized by most nucleated cells after activation of the transcription factors IRF-3 or IRF-7, NF-B, and activator protein 1 (18, 52, 68, 90, 118) . Type I IFN production is triggered intracellularly by products of viral replication, such as dsRNA (56, 67) and the viral ribonucleoprotein complex (103) . Several intracellular proteins respond to these stimuli by inducing the expression of type I IFNs. These proteins are the dsRNA-dependent protein kinase (PKR) (6, 97, 116) , the cellular enzymes TANK-binding kinase 1 (TBK1) (27) and IB kinase epsilon (IKKε) (27, 95) , the Rho GTPase Rac-1 (26), the retinoic acid-inducible gene I (RIG-I) (117), the melanoma differentiation-associated gene 5 (mda-5) (3), and the death domain-containing protein FADD (7). TLR signaling mediated by TBK1 and IKKε can also induce type I IFN production (91) .
Once synthesized, type I IFNs are secreted from the cells and bind their receptor in an autocrine or paracrine manner, initiating a signaling cascade that uses the signal transducers and activators of transcription 1 and 2 (STAT1/STAT2) (70, 96) and culminates in the synthesis of IFN-responsive proteins (57) . Genes coding for proteins with direct antiviral activity, such as PKR (which inhibits protein synthesis) (19) , MxA (which inhibits transcription) (93) , and 2Ј-5Ј-oligoadenylate synthetase (which activates RNaseL) (67, 78) , are the best-described type I IFN responsive genes. Nevertheless, type I IFNs participate in various other aspects of immunity (reviewed in reference 104).
They can directly affect B-cell development and function by influencing the generation of antibodies (15, 55) and can modulate the expression of proinflammatory cytokines, such as IL-6, transforming growth factor ␤, and IL-15, in other immune cells (14, 75, 119) . Type I IFN-induced proteins, such as IRF-1 (83) , participate in the development of NK cells (23, 79, 80) , in the expression of the inducible nitric oxide synthetase by macrophages (47, 71) , and in the development of Th1 immunity by inducing IL-12 p40 expression (59, 102) . In addition, the IFN-␥ inducible protein 10, also a type I IFN-induced protein, attracts Th1 cells to the site of infection, promoting the inflammatory response (22) .
The triggering of DC maturation and type I IFN synthesis upon virus infection are both crucial early events in the course of an antiviral immune response. Therefore, it is reasonable to speculate that type I IFNs may be involved in the induction of DC maturation after virus infection. These cytokines have been proposed as endogenous adjuvants based on their ability to induce the up-regulation of major histocompatibility complex and costimulatory molecules (CD80, CD86) on DCs (29, 55, 63, 89, 105) . Nevertheless, these molecules are up-regulated to a much greater extent when the cells are cotreated with dsRNA or lipopolysaccharide, indicating that type I IFNs are not able to fully mature DCs (38, 84) . Futhermore, cDCs do not secrete proinflammatory cytokines when treated with type I IFNs alone at various doses (61, 84) . Also, the upregulation of costimulatory molecules and secretion of inflammatory cytokines by cDCs occurs normally after infection with SeV or influenza virus in the presence of type I IFN-neutralizing antibodies or in type I IFN receptor-deficient cDCs (61) . In addition, efficient adaptive immunity is developed against these viruses in animals deficient in the type I IFN receptor (62a, 85) . This evidence suggests that responsiveness to type I IFNs is neither necessary nor sufficient for the induction of complete DC maturation and subsequent development of adaptive immunity to many viruses.
TLR-INDEPENDENT INDUCTION OF DC MATURATION BY VIRUSES
As discussed in the previous sections, a vast amount of data show that TLR stimulation can lead to DC maturation. In contrast, evidence supporting the requirement of TLRs for the development of antiviral immunity in vivo is limited. In fact, cDCs have been shown to mature normally in the absence of TLR signaling when infected with Newcastle disease virus (NDV) (38) , HSV (35), influenza virus, or SeV (62). TLR3 is not necessary for the generation of antiviral immunity against VSV, lymphocytic choriomeningitis virus (LCMV), MCMV, or reovirus (25) . Moreover, mice infected with influenza virus or SeV are able to clear the infection (as measured by titers of the virus in the lungs), recover from weight loss, and develop efficient adaptive immunity, including antibodies and cytotoxic T cells, in the absence of TLR signaling (62) . The absence of TLR7 and TLR9 expression from conventional human DCs (42, 43, 45) further supports the contention that recognition of viral genomic elements by TLRs is dispensable for the maturation of cDCs. All of these observations support the existence of a TLR-independent pathway for the induction of DC maturation capable of efficiently initiating adaptive antiviral immunity. UV-inactivated virus is unable to mature cDCs (61, 62) , suggesting that this pathway is triggered by virus replication intermediaries. Moreover, inactivated SeV or influenza virus fails to trigger Th1 immunity (60, 62) , further supporting an essential role for this replication-dependent pathway in the initiation of antiviral immunity.
Although type I IFNs are not necessary or sufficient to induce DC maturation (61), the observation that inactivated virus triggers neither maturation nor the release of type I IFNs from cDCs led us to hypothesize that molecular elements are shared between the induction of type I IFN synthesis and the TLR-independent pathway for DC maturation by viruses (61) . Indeed, strains of influenza virus or SeV with different abilities to induce type I IFN expression demonstrate a direct correlation between the strength with which a virus stimulates type I IFN synthesis and the ability of the virus to trigger the maturation of cDCs, independently of the secreted type I IFNs (61). The influenza virus PR8-⌬NS1 strain, which lacks the NS1 protein that confers a type I IFN antagonistic activity to the virus (30) , and the SeV strain Cantell, which is used broadly as a potent inducer of type I IFNs, are remarkably better at inducing the expression of costimulatory molecules (CD80 and CD86), proinflammatory cytokines (IL-1, IL-6, IL-12, and tumor necrosis factor alpha), and type I IFNs than their control virus counterparts, wild-type influenza PR8 virus and SeV strain 52 (61) .
These data support an intracellularly triggered pathway independent of TLR signaling and of secreted type I IFNs, but dependent on virus replication, as a major mechanism for the induction of cDC maturation (Fig. 1) . A model for the triggering of cDC maturation, where a virus replication intermediary triggers both type I IFN synthesis and the transcription of genes associated with DC maturation, is shown in Fig. 2 .
VIRAL AND CELLULAR ELEMENTS INVOLVED IN THE TRIGGERING OF TLR-INDEPENDENT DC MATURATION
Several pieces of evidence point toward dsRNA produced during the replication of viral genomes as the trigger for the TLR-independent pathway for DC maturation. First, the inability of inactivated viruses to mature DCs (60) (61) (62) indicates that viral replication, and not viral proteins or viral genomes themselves, is essential for the triggering of DC maturation. Second, the synthetic dsRNA analog poly(I:C) can induce DC maturation in the absence of TLR3, the described receptor for viral dsRNA (21, 38) . Third, dsRNA binding proteins are capable of antagonizing type I IFN production and DC maturation, strongly suggesting that this viral element is essential for the triggering of immunity (11, 88, 110) . Influenza viruses lack- ing the gene segment coding for the dsRNA-binding protein NS1 induce higher levels of type I IFNs and of DC maturation than influenza viruses coding for this antagonist (30, 61) . Moreover, the dsRNA-binding domain of NS1 specifically inhibits type I IFN induction by viral dsRNA (109) . Finally, viral defective interfering (DI) particles, incomplete viral genomes that replicate to higher levels than standard virus, while interfering with protein synthesis (40, 54) , enhance the DC maturation abilities of virus preparations (J. S. Yount, T. M. Moran, and C. B. López, unpublished data). This suggests that the dsRNA produced during the replication of the virus genome and not the dsRNA produced during mRNA synthesis participates in the triggering of DC maturation and type I IFN production.
A number of dsRNA-activated cellular proteins that mediate type I IFN synthesis have been identified. These proteins, including PKR, TBK1, IKKε, RIG-I, mda-5, and FADD (7, 27, 52, 103, 117, 118) , activate NF-B and IRF-3, both of which are involved in type I IFN synthesis and in the transcription of IL-12p35, an essential component of bioactive IL-12 (31, 76) . Thus, because the TLR-independent pathway for the triggering of DC maturation by live viruses shares common elements with the pathway resulting in type I IFN production, these cellular proteins must be viewed as good candidates for mediating virus-induced DC maturation (Fig. 2) .
PKR was the first cellular enzyme identified to respond to viral infection. It induces the activation of transcription factors essential for both type I IFNs and proinflammatory cytokine synthesis (52, 118) . Although PKR has been shown to participate in the induction of type I IFNs after the transfection of dsRNA into mouse DCs (21), it is not required for type I IFN induction or DC maturation after infection with live influenza virus, SeV, or NDV (10, 38, 61) . This contradiction illustrates the fundamental differences between an actual virus infection and the use of virus analogs, such as poly(I:C), that lack crucial characteristics such as the ability to replicate and concomitantly amplify the stimuli.
The helicase RIG-I binds dsRNA and is involved in the type I IFN response to virus infection (117) . This molecule activates the transcription factors IRF-3 and NF-B through the recently identified adaptor protein mitochondrial antiviral signaling protein (also called VISA, IPS-1, or Cardif) (49, 73, 94, 112) . RIG-I has been implicated in the induction of IL-12 and IL-6 in response to hepatitis C virus infection in transfected cell lines (28) . Although a direct effect of RIG-I in the maturation of DCs has not been yet demonstrated, this molecule is a promising candidate for triggering the induction of DC maturation by live viruses. In agreement with this idea, the enhanced production of dsRNA by virus in the presence of DI particles results in a heightened activation of the RIG-I signaling pathway. In fact, RIG-I is necessary for efficient type I IFN induction by DI particle-rich viruses that are also potent inducers of DC maturation (J. S. Yount, T. M. Moran, and C. B. López, unpublished data). Further studies are necessary to evaluate the role of TBK1, IKKε, FADD, and any other potential candidates for the triggering of DC maturation and initiation of adaptive immunity upon virus infection.
TLR-DEPENDENT TYPE I IFN IN THE DEVELOPMENT OF ANTIVIRAL IMMUNITY
Although DC maturation is independent of secreted type I IFNs for some viruses, other viruses, such as NDV, need to be complemented by this cytokine in order to induce complete DC maturation (38) . Because NDV stimulates mouse DC maturation very weakly compared with other viruses, such as SeV, it can be speculated that the strength of the signaling determines the requirement for type I IFN adjuvancy. pDCs that respond to virus infection by producing large amounts of type I IFN could provide this adjuvant effect through an intracellular pathway similar to that described for conventional DCs (39) and via TLR7-and TLR9-mediated signaling. Cells infected by viruses carrying a type I IFN antagonist, such as influenza virus, may also rely on exogenous type I IFNs for complete maturation.
Despite the effects of type I IFNs on different aspects of immunity, their in vivo role in the development of adaptive antiviral immune response is unclear. Type I IFN receptordeficient mice clear SeV, influenza virus, mouse mammary tumor virus, and rotavirus and generate efficient adaptive immunity against these viruses (4, 62a, 66, 85) . In contrast, mice deficient in the type I IFN receptor have an increased susceptibility to infection with LCMV, Semliki Forest virus, Theiler's virus, Venezuelan equine encephalitis (VEE) virus, and vesicular stomatitis virus (106, 107) . Evidence obtained from studies using different strains of LCMV and VEE virus suggests that the high virulence of some of the strains corresponds with low sensitivity to the antiviral effects of type I IFNs (81, 111) . This resistance to type I IFNs permits the virus to grow to high titers and to persist in the animals, exhausting the effector cells and thus rendering the immune response inadequate for the clearance of the virus (81) . Further studies are necessary to determine the actual role of TLR-dependent type I IFNs in antiviral immunity. It can be speculated that the generation of a type I IFN-rich environment by TLR-mediated pathways might be crucial for overcoming the ability of viruses to antagonize the innate type I IFN system and the TLR-independent pathway for DC maturation, thus allowing the development of adaptive immune responses.
PERSPECTIVES
The discovery of a novel pathway for the triggering of DC maturation and subsequent initiation of antiviral immunity represents the beginning of exciting research into the mechanisms utilized by the host to initiate an immune response upon virus infection. This pathway is independent of TLR signaling and secreted type I IFN but depends on virus replication, shares common elements with the type I IFN induction pathway, and seems to be essential for the activation of conventional DCs in the event of a virus infection. Although good cellular candidate molecules and prospective viral elements involved in this pathway are emerging, detailed studies are needed to determine their definitive role in this process. The identification of specific cellular molecules responsible for these events could be of enormous value in the development of antiviral therapies and in the design of effective vaccines. 
